Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$127.21 USD
+0.11 (0.09%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $127.29 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Sarepta Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,676 | 1,989 | 2,116 | 1,939 | 1,125 |
Receivables | 400 | 215 | 153 | 101 | 91 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 323 | 204 | 186 | 232 | 171 |
Other Current Assets | 180 | 150 | 149 | 213 | 82 |
Total Current Assets | 2,579 | 2,558 | 2,604 | 2,485 | 1,469 |
Net Property & Equipment | 227 | 180 | 191 | 190 | 130 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 191 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 8 | 14 | 14 | 13 |
Deposits & Other Assets | 137 | 318 | 293 | 204 | 174 |
Total Assets | 3,265 | 3,128 | 3,148 | 2,985 | 1,823 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 165 | 96 | 77 | 111 | 68 |
Current Portion Long-Term Debt | 105 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 315 | 419 | 272 | 194 | 186 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 50 | 105 | 104 | 111 | 11 |
Total Current Liabilities | 654 | 620 | 453 | 416 | 265 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 437 | 485 | 574 | 663 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,133 | 1,544 | 1,097 | 992 | 682 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 41 | 37 | 55 | 71 | 10 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,405 | 2,743 | 2,220 | 2,223 | 1,005 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 5,305 | 4,297 | 4,135 | 3,610 | 3,112 |
Retained Earnings | -4,446 | -3,910 | -3,207 | -2,848 | -2,294 |
Other Equity | 1 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 859 | 385 | 928 | 762 | 818 |
Total Liabilities & Shareholder's Equity | 3,265 | 3,128 | 3,148 | 2,985 | 1,823 |
Total Common Equity | 859 | 385 | 928 | 762 | 818 |
Shares Outstanding | 93.50 | 87.70 | 87.00 | 78.90 | 74.50 |
Book Value Per Share | 9.19 | 4.39 | 10.67 | 9.65 | 10.98 |
Fiscal Year End for Sarepta Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,460 | 1,391 | 1,676 | 1,734 | 1,861 |
Receivables | 360 | 379 | 400 | 319 | 237 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 486 | 374 | 323 | 244 | 227 |
Other Current Assets | 377 | 322 | 180 | 154 | 148 |
Total Current Assets | 2,684 | 2,465 | 2,579 | 2,451 | 2,473 |
Net Property & Equipment | 276 | 249 | 227 | 212 | 189 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 205 | 208 | 191 | 176 | 167 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 136 | 176 | 137 | 137 | 163 |
Total Assets | 3,424 | 3,224 | 3,265 | 3,110 | 3,126 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 107 | 92 | 165 | 88 | 110 |
Current Portion Long-Term Debt | 92 | 106 | 105 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 350 | 283 | 315 | 322 | 327 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 139 | 128 | 50 | 40 | 62 |
Total Current Liabilities | 688 | 609 | 654 | 451 | 499 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 325 | 325 | 437 | 485 | 485 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,135 | 1,134 | 1,133 | 1,237 | 1,236 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 55 | 41 | 38 | 36 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,347 | 2,263 | 2,405 | 2,345 | 2,384 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 5,482 | 5,372 | 5,305 | 5,257 | 5,193 |
Retained Earnings | -4,404 | -4,410 | -4,446 | -4,492 | -4,451 |
Other Equity | -1 | -1 | 1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,077 | 961 | 859 | 764 | 741 |
Total Liabilities & Shareholder's Equity | 3,424 | 3,224 | 3,265 | 3,110 | 3,126 |
Total Common Equity | 1,077 | 961 | 859 | 764 | 741 |
Shares Outstanding | 94.50 | 94.50 | 93.50 | 93.50 | 93.20 |
Book Value Per Share | 11.40 | 10.17 | 9.19 | 8.17 | 7.96 |